Cargando…

Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer

BACKGROUND: The 2018 Guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT), according to which the results should be available to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Chao, Wei, Bing, Liu, Xiaohui, Meng, Lin, Zhao, Chengzhi, Chang, Yuxi, Sun, Rui, Zhang, Zhongxian, Yu, Yang, Ma, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848391/
https://www.ncbi.nlm.nih.gov/pubmed/35282093
http://dx.doi.org/10.21037/atm-21-6230
_version_ 1784652239546089472
author Shi, Chao
Wei, Bing
Liu, Xiaohui
Meng, Lin
Zhao, Chengzhi
Chang, Yuxi
Sun, Rui
Zhang, Zhongxian
Yu, Yang
Ma, Jie
author_facet Shi, Chao
Wei, Bing
Liu, Xiaohui
Meng, Lin
Zhao, Chengzhi
Chang, Yuxi
Sun, Rui
Zhang, Zhongxian
Yu, Yang
Ma, Jie
author_sort Shi, Chao
collection PubMed
description BACKGROUND: The 2018 Guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT), according to which the results should be available to the treating oncologist within 10 working days. This article focused on the application process of a new protocol for pathological diagnosis and gene testing pathway and a sample collector. We want to solve the problem that there are not enough puncture samples for gene testing, and the benchmark turnaround time of gene detection was long in clinic. METHODS: In this study, we established and validated a new protocol for a pathological diagnosis and treatment pathway that was tested in the Henan Cancer Hospital, China. The “Biology collector (BIOCO)” tool was designed by our team, was made of polyvinyl chloride (PVC) material (patent application number is 201820902335.6). It consisted of two round magnets on the collector that can be adsorbed on the microtome blade holder, thus making it to move arbitrarily. It collected specimens that were discarded when the wax block was trimmed. We analyzed the TAT, testing accuracy and anti-pollution of new protocol based on BIOCO, compared with the conventional process based on the Routine Collection (ROUCO). RESULTS: The new pathway adopts a parallel approach to conventional pathology and molecular pathology, which significantly shortens the TAT to 4–6 days. The use of the BIOCO tool can effectively save pathological samples, avoid cross-contamination, and reduce the time delay caused by re-sampling. Most importantly, its accuracy and effectiveness are consistent with conventional collection methods. CONCLUSIONS: The new diagnosis and treatment pathway based on the BIOCO collector can be used as a practical approach for the molecular diagnostic platform of the hospital pathology department.
format Online
Article
Text
id pubmed-8848391
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-88483912022-03-10 Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer Shi, Chao Wei, Bing Liu, Xiaohui Meng, Lin Zhao, Chengzhi Chang, Yuxi Sun, Rui Zhang, Zhongxian Yu, Yang Ma, Jie Ann Transl Med Original Article BACKGROUND: The 2018 Guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT), according to which the results should be available to the treating oncologist within 10 working days. This article focused on the application process of a new protocol for pathological diagnosis and gene testing pathway and a sample collector. We want to solve the problem that there are not enough puncture samples for gene testing, and the benchmark turnaround time of gene detection was long in clinic. METHODS: In this study, we established and validated a new protocol for a pathological diagnosis and treatment pathway that was tested in the Henan Cancer Hospital, China. The “Biology collector (BIOCO)” tool was designed by our team, was made of polyvinyl chloride (PVC) material (patent application number is 201820902335.6). It consisted of two round magnets on the collector that can be adsorbed on the microtome blade holder, thus making it to move arbitrarily. It collected specimens that were discarded when the wax block was trimmed. We analyzed the TAT, testing accuracy and anti-pollution of new protocol based on BIOCO, compared with the conventional process based on the Routine Collection (ROUCO). RESULTS: The new pathway adopts a parallel approach to conventional pathology and molecular pathology, which significantly shortens the TAT to 4–6 days. The use of the BIOCO tool can effectively save pathological samples, avoid cross-contamination, and reduce the time delay caused by re-sampling. Most importantly, its accuracy and effectiveness are consistent with conventional collection methods. CONCLUSIONS: The new diagnosis and treatment pathway based on the BIOCO collector can be used as a practical approach for the molecular diagnostic platform of the hospital pathology department. AME Publishing Company 2022-01 /pmc/articles/PMC8848391/ /pubmed/35282093 http://dx.doi.org/10.21037/atm-21-6230 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Shi, Chao
Wei, Bing
Liu, Xiaohui
Meng, Lin
Zhao, Chengzhi
Chang, Yuxi
Sun, Rui
Zhang, Zhongxian
Yu, Yang
Ma, Jie
Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
title Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
title_full Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
title_fullStr Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
title_full_unstemmed Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
title_short Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
title_sort implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848391/
https://www.ncbi.nlm.nih.gov/pubmed/35282093
http://dx.doi.org/10.21037/atm-21-6230
work_keys_str_mv AT shichao implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT weibing implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT liuxiaohui implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT menglin implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT zhaochengzhi implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT changyuxi implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT sunrui implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT zhangzhongxian implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT yuyang implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer
AT majie implementationofapathologicaldiagnosisandtreatmentpathwaymayimprovethemoleculardetectionoflungcancer